TB-500 10 mg

TB-500 peptide is a synthetic full-length analog of thymosin beta-4, a 43-residue actin-binding research peptide abundantly expressed across many mammalian cell types. As a synthetic reference compound, TB-500 is supplied for use in actin-binding research, cytoskeletal dynamics research models, and cellular-process research in controlled laboratory settings.

TB-500 peptide is investigated for its interaction with monomeric G-actin, a core component of the cytoskeletal dynamics research system. In laboratory research studies, the parent thymosin beta-4 sequence has been characterized as a 1:1 actin-sequestering peptide that engages G-actin and modulates the equilibrium between monomeric and filamentous actin in cellular research models (Huff et al., 2001, International Journal of Biochemistry and Cell Biology). This actin-binding profile makes TB-500 a widely used reference compound in laboratory research studies of cytoskeletal dynamics research and cellular-process research signalling.

Beyond actin-binding research, TB-500 peptide has also been investigated in laboratory research studies examining endothelial cellular-process research models, inflammatory-pathway research, and structure-activity research comparing the full-length thymosin beta-4 sequence with discrete active-site fragments such as the heptapeptide LKKTETQ (Sosne et al., 2010, Annals of the New York Academy of Sciences). These investigations have positioned TB-500 as an experimental research compound of interest in studies of cytoskeletal dynamics research and cellular-pathway research models.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Thymosin beta-4 is a 43-amino-acid acidic peptide first isolated from thymic tissue and subsequently identified as one of the most abundant intracellular actin-sequestering peptides in mammalian cell types. It functions as a 1:1 G-actin-binding research peptide and contributes to the maintenance of a pool of monomeric actin available for rapid cytoskeletal reorganization in cellular research models.

TB-500 is supplied as a synthetic full-length analog of the thymosin beta-4 sequence, allowing laboratory research studies to use a defined reference compound for actin-binding research and cytoskeletal dynamics research. The sequence retains the central LKKTET actin-binding motif (residues 17-22), which has been mapped through mutational and structural research as the principal contact region with G-actin in research models.

This positioning at the intersection of cytoskeletal dynamics research, cellular-process research, and structure-activity research has made TB-500 an experimental research compound of considerable interest in laboratory research studies of actin-binding pharmacology, endothelial cellular-process research, and comparative thymosin beta-4 fragment research.

1. Actin-Binding and Cytoskeletal Dynamics Research

TB-500 engages monomeric G-actin in a 1:1 stoichiometry through its central LKKTET actin-binding motif. In laboratory research studies, this interaction sequesters G-actin and modulates the equilibrium between monomeric and filamentous actin populations, supporting investigations into cytoskeletal dynamics research and cellular-process research models.

2. Cellular-Process Signalling Research

TB-500 has been investigated in cellular research models for its interaction with endothelial and epithelial cell migration pathways. Research models indicate that the full-length thymosin beta-4 sequence engages cellular-process signalling research relevant to cellular-pathway research and structure-activity research with discrete actin-binding fragments such as LKKTETQ.

3. Inflammatory-Pathway Research

Laboratory research studies have examined how TB-500 modulates inflammatory-pathway research markers in cellular and animal research models. These investigations are relevant to cytokine-signalling research and comparative research on thymosin beta-4 active-site fragments.

4. Structure-Activity Research

By supplying the full-length 43-residue sequence, TB-500 enables comparative research alongside discrete fragments such as the heptapeptide LKKTETQ (residues 17-23). This supports structure-activity research investigating how isolated actin-binding domains compare to the parent peptide in actin-binding research and cellular-process research models.

Research Applications

Conclusion

TB-500 is a synthetic full-length thymosin beta-4 research peptide that engages monomeric G-actin through its central LKKTET motif and supports laboratory research studies of cytoskeletal dynamics research, cellular-process research, and inflammatory-pathway research. Its defined sequence and 1:1 actin-binding profile make it a valuable reference compound for laboratory research studies of actin-binding pharmacology and comparative research with thymosin beta-4 active-site fragments.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.